OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Reviews Drug Discovery is 81. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
New target for anorexia	1736
Alzheimer antibody rush begins, as efficacy concerns remain	1667
Will psychedelics be ‘a revolution in psychiatry’?	1051
Generating neurons in the adult brain	1039
First clinical test of an in vivo CRISPR candidate shows deep protein knockout potential	909
Upcoming market catalysts in Q3 2021	901
New CAR’s bells and whistles	725
Brain glucose mediates amphotericin B tolerance	687
Acyl-lysine reader inhibitor blocks AML progression	654
Identifying selective PI3KC2α inhibitors	608
Putting a PIN in pancreatic cancer	517
A cancer drug wish list	483
FDA approves first-in-class NK3 receptor antagonist for hot flushes	455
Hypoimmune iPSCs escape immune detection	453
Do fourth-generation EGFR inhibitors showcase the future of kinase inhibitors?	440
A spirulina-based biomanufacturing platform	379
Small-molecule screens for targeting non-coding RNA	377
Vertex’s NaV1.8 inhibitor passes phase II pain point	370
Monoclonal antibody treats yellow fever	363
DENV inhibitor effective in non-human primates	352
Decrypting drug action at the level of PTMs	347
PKN3: a target in cancer metastasis	344
A new path to targeted protein degradation?	339
FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform	337
Pandemic vaccines: a formidable challenge for pharmacovigilance	336

Neurons give metastatic cells a push	335
Apolipoprotein L2 inhibitor mitigates fibrosis	334
RAS-targeted therapies	314
ASO targets DNA repair protein to combat Huntington disease	313
PKC modulator promotes remyelination	300
FDA approves new non-opioid pain drug	251
Chemical engineering of CRISPR–Cas systems for therapeutic application	247
Bluebird Bio’s cut-price sale highlights challenges for gene therapy field	238
Non-antibiotic drug network reveals new leads for antibiotics	233
Kinase inhibitor rescues the liver	229
AI serves up target and inhibitor for lung fibrosis	228
FDA approves first complement factor D inhibitor	225
Synthesizing portimines	224
mRNA flu shots move into trials	221
A ROS-mediated resistance pathway to anticancer drugs	206
The importance of persistence in cancer drug development	202
Novo Nordisk and GlaxoSmithKline buy into RNAi	187
FDA approves first Friedreich’s ataxia drug	184
New naming scheme for antibodies drops the -mab stem	180
Overcoming ICB resistance in lung cancer	173
Allosteric adenosine receptor modulator alleviates pain	173
2024 FDA approvals exceed average number but have lower sales projections	168
Lipid nanoparticle ferries therapeutic mRNA to the placenta	162
Rediscovering hygromycin A for Lyme disease treatment	152
Towards polio eradication	143
Massive misuse of chemical probes undermines the utility of these tools	139
Treating cannabis use disorder	138
What’s next for an immuno-oncology powerhouse?	137
Stalled molecular motor inhibits tumour growth	137
The pipeline and market for migraine drugs	135
Shifts in the clinical trial landscape	135
The KRAS crowd targets its next cancer mutations	132
mRNA-encoded monoclonal antibody fights CHIKV	130
Nanoparticle chirality sets the dial on immunogenicity	130
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval	127
FDA new drug approvals in Q1 2023	124
Eli Lilly spends $3.2 billion on Morphic’s oral integrin inhibitor for inflammatory bowel disease	116
Comprehensive measurement of biopharmaceutical R&D investment	114
Epigenetic editor silences prion protein	112
Clinical trial strategies for rare neurodevelopmental disorders: challenges and opportunities	106
GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billion	103
Understanding the effects of antibiotic combinations	103
Ipsen buys Epizyme for US$247 million	100
Promoting tissue repair after heart attack	97
Weeding out toxic RNA in Huntington disease	96
Pasting in large DNA sequences	95
Understanding long-lasting ketamine effects	95
Targeting tumour-associated bacteria	89
Bacteria tag tumours for CAR-T cell attack	88
FDA new drug approvals in Q1 2021	88

First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer	86
The improving benefit–risk balance of phase I cancer trials	84
A specific biomarker for insoluble tau	84
Improving circular RNA protein yields	83
Pfizer buys Biohaven’s migraine drugs for $11.6 billion	83
Vaccine exposes tumours to immune cell attack	83
Upcoming market catalysts in Q1 2023	81
Upcoming market catalysts in Q3 2022	81